Janus Henderson Group PLC Decreases Stake in Certara, Inc. (NASDAQ:CERT)

Janus Henderson Group PLC decreased its holdings in Certara, Inc. (NASDAQ:CERT) by 70.0% in the 3rd quarter, according to its most recent Form 13F filing with the SEC. The institutional investor owned 57,014 shares of the company’s stock after selling 132,856 shares during the quarter. Janus Henderson Group PLC’s holdings in Certara were worth $667,000 as of its most recent filing with the SEC.

Other hedge funds and other institutional investors also recently bought and sold shares of the company. Wasatch Advisors LP boosted its holdings in Certara by 22.4% during the third quarter. Wasatch Advisors LP now owns 9,015,941 shares of the company’s stock worth $105,577,000 after buying an additional 1,651,076 shares in the last quarter. Geneva Capital Management LLC boosted its stake in shares of Certara by 0.7% during the 3rd quarter. Geneva Capital Management LLC now owns 5,510,209 shares of the company’s stock worth $64,525,000 after acquiring an additional 37,392 shares in the last quarter. Massachusetts Financial Services Co. MA grew its holdings in shares of Certara by 40.7% in the 3rd quarter. Massachusetts Financial Services Co. MA now owns 3,901,898 shares of the company’s stock worth $45,691,000 after acquiring an additional 1,128,006 shares during the period. Dimensional Fund Advisors LP increased its stake in Certara by 9.7% in the 2nd quarter. Dimensional Fund Advisors LP now owns 3,079,023 shares of the company’s stock valued at $42,643,000 after purchasing an additional 273,095 shares in the last quarter. Finally, Brown Brothers Harriman & Co. acquired a new position in Certara during the third quarter worth $27,292,000. Institutional investors and hedge funds own 73.96% of the company’s stock.

Certara Stock Performance

NASDAQ CERT opened at $11.47 on Friday. The company has a current ratio of 2.86, a quick ratio of 2.86 and a debt-to-equity ratio of 0.28. The company has a market capitalization of $1.85 billion, a PE ratio of -57.35, a price-to-earnings-growth ratio of 5.86 and a beta of 1.53. The business’s 50-day moving average price is $10.84 and its 200 day moving average price is $12.63. Certara, Inc. has a twelve month low of $9.41 and a twelve month high of $19.87.

Certara (NASDAQ:CERT) last announced its quarterly earnings data on Wednesday, November 6th. The company reported $0.13 earnings per share (EPS) for the quarter, beating the consensus estimate of $0.11 by $0.02. The company had revenue of $94.80 million during the quarter, compared to analysts’ expectations of $95.51 million. Certara had a negative net margin of 8.34% and a positive return on equity of 3.43%. The business’s quarterly revenue was up 10.7% compared to the same quarter last year. During the same period in the previous year, the company earned $0.06 EPS. On average, research analysts predict that Certara, Inc. will post 0.28 earnings per share for the current year.

Insiders Place Their Bets

In other news, insider Patrick F. Smith sold 5,409 shares of the business’s stock in a transaction dated Monday, October 7th. The stock was sold at an average price of $11.03, for a total transaction of $59,661.27. Following the completion of the sale, the insider now owns 50,091 shares in the company, valued at approximately $552,503.73. The trade was a 9.75 % decrease in their position. The sale was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through this link. 2.39% of the stock is currently owned by insiders.

Wall Street Analyst Weigh In

CERT has been the subject of several research reports. Robert W. Baird cut their price target on Certara from $18.00 to $13.00 and set a “neutral” rating for the company in a research note on Tuesday, November 5th. Barclays lowered their price target on shares of Certara from $14.00 to $12.00 and set an “equal weight” rating on the stock in a research report on Thursday, November 7th. Finally, UBS Group upgraded Certara from a “neutral” rating to a “buy” rating and set a $16.00 price objective for the company in a research report on Friday, September 27th. Six research analysts have rated the stock with a hold rating and two have given a buy rating to the stock. According to MarketBeat, the company currently has a consensus rating of “Hold” and an average target price of $15.92.

Certara Profile

Certara, Inc, together with its subsidiaries, provides software products and technology-enabled services to customers for biosimulation in drug discovery, preclinical and clinical research, regulatory submissions, and market access in the United States and internationally. It offers solutions for model-informed drug development, as well as biosimulation solution used to predict both pharmacokinetics and pharmacodynamics.